Table 1.
Characteristics of study participants.
| All n = 82 |
COVID-19 Recovered n = 40 |
Non-COVID-19 n = 42 |
p | |
|---|---|---|---|---|
| Age (years) | 0.58 * | |||
| M ± SD | 39.9 ± 9.8 | 39.3 ± 10.7 | 39.9 ± 9.8 | |
| Me (Q1–Q3) | 38.0 (31.0–47.0) | 36.0 (29.5–48.0) | 38.0 (31.0–47.0) | |
| Min–Max | 25.0–64.0 | 25.0–64.0 | 25.0–64.0 | |
| Weight (kg) | 0.62 * | |||
| M ± SD | 77.9 ± 16.8 | 78.9 ± 18.6 | 77.0 ± 15.1 | |
| Me (Q1–Q3) | 77.5 (67.0–87.0) | 79.0 (66.0–89.5) | 76.5 (67.0–82.0) | |
| Min–Max | 45.0–135.0 | 45.0–135.0 | 50.0–116.0 | |
| Height (cm) | 0.43 * | |||
| M ± SD | 171.5 ± 8.9 | 172.4 ± 10.0 | 170.8 ± 7.8 | |
| Me (Q1–Q3) | 173.0 (164.0–180.0) | 173.0 (163.5–180.5) | 172.5 (164.0–176.0) | |
| Min–Max | 155.0–189.0 | 157.0–189.0 | 155.0–184.0 | |
| BMI (kg/m2) | 0.92 * | |||
| M ± SD | 26.4 ± 4.7 | 26.4 ± 5.2 | 26.3 ± 4.3 | |
| Me (Q1–Q3) | 26.3 (22.8–29.4) | 26.2 (22.8–29.7) | 26.3 (23.3–29.0) | |
| Min–Max | 17.4–37.8 | 17.4–37.8 | 18.9–36.3 | |
| Sex (female) n (%) | 49 (60%) | 23 (58%) | 26 (62%) | 0.68 ** |
| Blood group n (%) | 0.36 ** | |||
| O | 17 (23%) | 5 (14%) | 12 (31%) | |
| AB | 8 (11%) | 5 (14%) | 3 (8%) | |
| A | 33 (44%) | 17 (49%) | 16 (41%) | |
| B | 6 (22%) | 8 (23%) | 11 (20%) | |
| Rh factor n (%) | 0.12 ** | |||
| Rh − | 14 (19%) | 4 (11%) | 10 (26%) | |
| Rh + | 60 (81%) | 31 (89%) | 29 (74%) | |
| Chronic disease n (%) | ||||
| Hypertension (Yes) | 8 (10%) | 5 (13%) | 3 (7%) | 0.41 ** |
| Diabetes (Yes) | 2 (2%) | 1 (3%) | 1 (2%) | 0.97 ** |
| Thyroid disease (Yes) | 7 (9%) | 4 (10%) | 4 (7%) | 0.64 ** |
Abbreviations: n, number of participants; M, mean; Me, median; Min, minimum value; Max, maximum value; Q1, lower quartile; Q3, upper quartile; SD, standard deviation; p, level of statistical significance. Notes: * t-test for independent samples; ** χ2 test.